Moreno-Ramos, Manuel JoséSánchez-Piedra, CarlosMartínez-González, OlgaRodríguez-Lozano, CarlosPérez-García, CarolinaFreire, MercedesCampos, CristinaCáliz-Caliz, RafaelCalvo, JerusalemBlanco-Madrigal, Juan M.Pérez-Gómez, AnaMoreno-Martínez, María JoséLinares, LuisSánchez-Alonso, FernandoSastré, CarlosCastrejón, Isabel2022-12-052022-12-052022Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-Garcia C, Freire M, et al. Real-world effectiveness and treatment retention of secukinumab in patients with psoriatic arthritis and axial spondyloarthritis: a descriptive observational analysis of the spanish BIOBADASER registry. Rheumatol Ther. 2022 Aug; 9(4): 1031- 47. DOI: 10.1007/s40744-022-004462198-6576http://hdl.handle.net/10230/55082Rheumatic diseases are extensively managed with biological disease-modifying antirheumatic drugs (bDMARDs), but a notable proportion of patients withdraw in the long term because of lack of effectiveness, adverse events, or the patient's decision. The present real-world analysis showed the effectiveness, retention, and safety data collected in the Spanish BIOBADASER registry for patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA, including ankylosing spondylitis (AS) and non-radiographic axSpA) treated with secukinumab, a human antibody against interleukin-17A (IL-17A), for more than 12 months. Six hundred and thirty-nine patients were analysed (350, 262, and 27 PsA, AS, and nr-axSpA patients, respectively). The results showed an improvement in the disease activity after 1 year of treatment, in terms of decreases of the mean Disease Activity Score 28 using C-reactive protein (DAS28-CRP), the mean Disease Activity Psoriatic Arthritis (DAPSA) score, swollen joint counts (SJC), and tender joint counts (TJC) in PsA patients and decreases in the mean Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the mean Ankylosing Spondylitis Disease Activity Score (ASDAS) in axSpA patients. This improvement was maintained or increased after 2 and 3 years of treatment, indicating that secukinumab is effective in both naïve and non-responder patients. Retention rates were higher when secukinumab was used as the first-line biological treatment, although they were also adequate in the second and third lines of treatment. Collected safety data were consistent with previous reports.application/pdfengCopyright © Moreno-Ramos MJ, Sanchez-Piedra C, Martínez-González O, Rodríguez-Lozano C, Pérez-Garcia C, Freire M, et al. 2022, corrected publication 2022. Open Access. This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.info:eu-repo/semantics/articlehttp://dx.doi.org/10.1007/s40744-022-00446Ankylosing spondylitisAxial spondyloarthritisIL-17Non-radiographic axial spondyloarthrtisPsoriatic arthritisSecukinumabinfo:eu-repo/semantics/openAccess